908 Devices Launches MAVERICK for Real-Time In-Line Monitoring of Multiple Bioprocess Parameters
September 18 2023 - 7:00AM
Business Wire
MAVERICK is a Raman-based PAT solution that
requires no complex modeling
908 Devices Inc. (Nasdaq: MASS), a pioneer of purpose-built
handheld and desktop devices for chemical and biochemical analysis,
announces the launch of MAVERICK, an optical in-line analyzer that
provides real-time monitoring and control of glucose, lactate, and
total biomass in mammalian cell cultures, in addition to rich
process fingerprint data to support large-scale efforts in
predictive bioprocess modeling. MAVERICK is the first turn-key
device to utilize Raman spectroscopy for bioprocess control, with
no modeling and development required. With its in-line optical
sampling probe, biopharmaceutical scientists and engineers can
quickly develop their cell culture media and design feeding and
control strategies.
MAVERICK offers all the advantages of Raman spectroscopy without
the cost and complexities associated with conventional
spectroscopic methods. MAVERICK’s purpose-built de novo models
automatically process Raman spectra from a wide variety of culture
media types and cell lines, delivering actionable process
parameters or direct process control actions. Open access to the
raw process spectral data also enables Artificial Intelligence (AI)
/ Machine Learning (ML) experts to extend MAVERICK’s capabilities
for more advanced predictive control of critical process parameters
or quality attributes.
“Traditional Raman-based analyzers require a sharp learning
curve for the user which is time-consuming for initial model
building and continued model updates,” said Dr. Seongkyu Yoon,
Professor in the Department of Chemical Engineering and the Ward
Endowed Professor in Biomedical Sciences at the University of
Massachusetts-Lowell. “With MAVERICK, all the hurdles of
traditional Raman have been overcome. This device provides very
good measurements independently of cell line, media, and scale,
which is very beneficial.”
The MAVERICK hub can monitor up to six bioreactor modules
simultaneously, with independent analog/digital control of feed
systems for each. Remote real-time web access to bioreactor status
and settings is also supported through the MAVERICK hub.
Biopharmaceutical process development scientists and manufacturers
will be able to enhance process understanding and implement dynamic
control strategies quicker and easier, leading to faster time to
market and more robust and efficient processes.
“As the biopharmaceutical industry adopts Process Analytical
Technologies to drive the advancement of Biopharma 4.0, scientists
need an array of tools that enable them to monitor and control
their process in real time,” said Christopher D. Brown, Chief
Product Officer and co-founder of 908 Devices. “We are addressing
this need with our full complement of devices. With MAVERICK, we
are introducing a new platform that offers easy-to-integrate
in-line analysis and control without the need for substantial
expert configuration or set-up. In addition, as a
spectroscopic-based device, MAVERICK is extensible to other
analytes and parameters.”
908 Devices experts will share more details about MAVERICK
during the following events, including at the BioProcess
International (BPI) conference in Boston:
- Webinar (virtual) – September 18 at 11am ET –
Chris Brown, CPO and co-founder, and Graziella Piras, Senior
Director of Strategic Marketing at 908 Devices, will co-present
this webinar about advanced in-line monitoring for bioprocessing,
which will introduce the MAVERICK solution to the marketplace.
- Scientific presentation – September 19 at 9:30am ET –
Chris Brown will host a session within the Cell Culture Track at
BPI Boston titled, “In-line monitoring of bioprocess parameters for
the 21st century,” which will outline advancements in Biopharma 4.0
and the current state of spectroscopy-based approaches.
- Breakfast seminar – September 19 at 10am ET – Nick
Randall, Bioprocessing Product Manager at 908 Devices, will conduct
a talk at BPI Boston about “out-of-the-box implementation of
optical monitoring of critical process parameters,” which will
showcase the benefits and use cases of MAVERICK.
- You can also find 908 Devices at BPI Boston at booth
#860.
- Scientific presentation – September 28 at 9am CET –
During the World Smart Bioprocessing Summit-Pharma 4.0 in Berlin,
Steve Driscoll, Senior Scientist at 908 Devices, will speak about
the strengths and limitations of in-line multivariate bioprocess
analysis. You can also find 908 Devices at Table 6 during the
summit.
MAVERICK is part of 908 Devices’ suite of devices to help
expedite bioprocessing development, including MAVEN – introduced
earlier this year -- and REBEL. To learn more about 908 Devices,
please visit: 908devices.com.
About 908 Devices 908 Devices is revolutionizing chemical
and biochemical analysis with its simple handheld and desktop
devices, addressing critical-to-life applications. The Company’s
devices are used at the point-of-need to interrogate unknown and
invisible materials and provide quick, actionable answers to
directly address some of the most critical problems in life
sciences research, bioprocessing, pharma/biopharma, forensics and
adjacent markets. The Company is headquartered in the heart of
Boston, where it designs and manufactures innovative products that
bring together the power of mass spectrometry, microfluidic
sampling and separations, software automation, and machine
learning.
Forward Looking Statements This press release includes
“forward looking statements” within the meaning of the Private
Securities Litigation Reform Act of 1995. All statements other than
statements of historical facts are forward-looking statements,
including, without limitation, statements regarding the expected
uses and capabilities of the Company’s products. Words such as
“may,” “will,” “expect,” “plan,” “anticipate,” “estimate,” “intend”
and similar expressions (as well as other words or expressions
referencing future events, conditions or circumstances) are
intended to identify forward-looking statements. These
forward-looking statements are based on management’s current
expectations and involve known and unknown risks, uncertainties and
assumptions which may cause actual results to differ materially
from any results expressed or implied by any forward-looking
statement, including the risks outlined under “Risk Factors” and
elsewhere in the Company’s filings with the Securities and Exchange
Commission which are available on the SEC's website at www.sec.gov.
Additional information will be made available in the Company’s
annual and quarterly reports and other filings that it makes from
time to time with the SEC. Although the Company believes that the
expectations reflected in its forward-looking statements are
reasonable, it cannot guarantee future results. The Company has no
obligation, and does not undertake any obligation, to update or
revise any forward-looking statement made in this press release to
reflect changes since the date of this press release, except as may
be required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230918740819/en/
Media Katie Johnston PAN Communications for 908 Devices
908devices@pancomm.com
Investor Carrie Mendivil IR@908devices.com
908 Devices (NASDAQ:MASS)
Historical Stock Chart
From Jul 2024 to Jul 2024
908 Devices (NASDAQ:MASS)
Historical Stock Chart
From Jul 2023 to Jul 2024